This trial is evaluating whether Low Level Laser Therapy will improve 1 primary outcome and 5 secondary outcomes in patients with Dyschezia. Measurement will happen over the course of 4 weeks.
This trial requires 20 total participants across 2 different treatment groups
This trial involves 2 different treatments. Low Level Laser Therapy is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
The present findings do not provide evidence of a cure for dyschezia. Further, only a small number of patients will be left with persistent symptoms once the initial therapeutic step is complete.
Dyschezia is a condition where one experiences chronic and persistent constipation or other symptoms of dysuria, excessive passage of stool or faeces followed by a feeling of incomplete evacuation or abdominal distension which is accompanied by a desire to pass faecal matter. Many women have frequent and unremitting dyspnoea, diarrhoea and constipation. Women presenting with dyspnoea, diarrhoea and constipation have a high index of suspicion that dyschezia may be present and appropriate investigation is warranted.
Dyschezia is a condition that does not have a known cause. Recent findings, dyschezia was diagnosed in only 10% of the patients when examined in-person by a specialist. All patients presented chronic symptoms.
We estimate the prevalence of dyschezia is relatively high in the United States. Women and persons 20 years or older are twice as likely to be affected, compared with men. Older age increases the risk of dyschezia; people over 60 years of age are almost twelve times more likely to have dyschezia.
While many conditions may present with dyspepsia-like symptoms, an exact etiology is not evident in many cases. Treatments include empiric antibiotic therapy for Helicobacter-related dysentry, or more specific treatment options such as empiric or adjunctive H2-receptor antagonists/proton pump inhibitors. Specific Helicobacter screening, proton pump inhibitors and cimetidine or tinidazole is also appropriate in some cases. The treatment of dysentery and celiac disease should be taken into account in some of the conditions causing dyspnea. Treatments must be tailored to the specific presentation of dyspnea.
Dyschezia is a common and often unexplained condition with a variety of causes. The management of dyschezia may involve simple behavioural changes or, in refractory cases, the use of multiple therapies that can be grouped into 3 groups: medication, alternative therapies, and alternative medicine. While a small number of medical treatments are effective for a number of causes, many of these therapies appear to be only moderately effective and of unclear benefit.
Dyschezia is not as serious as many might expect, but a serious problem that can cause discomfort for a person, particularly in social situations. Dyschezia may be treated with a standard-care medication such [metoclopramide] or an unconventional medicine, [loperamide]. Doctors and patients might consider seeking help from a certified dyschezia counselor.\n
Patients with symptomatic IBS-D experienced less symptom severity, and reported more overall improvement in symptoms, than those receiving a placebo treatment. The patients who took the low-level red laser radiation reported more improvements after 3 months compared to the placebo group. We can conclude that low-level red laser has significant therapeutic benefits in IBS-D.
Dyschezia is a common problem for many people. If you have a doctor, ask him or her to diagnose and treat you. To help treat dyschezia that may not be painful, the National Institutes of Health recommends that women [who are not pregnant or breastfeeding; are over age 70; have an enlarged uterus or are [in the first or second trimester of pregnancy] eat foods high in [folic acid] and fiber, eat more fruit and vegetables each day, and limit intake of alcohol and caffeine.
Overall dyschezia starts to develop at a rate of 11% at the age of 21 years. At this same age, 1% experience [severe symptoms] of chronic dyschezia. Furthermore, dyschezia can be caused by a number of factors, and it is unclear if dyschezia is a chronic condition. However, [if dyschezia is a chronic condition, then it is inevitable that symptomatic patients will develop dyschezia again as ages past 71 years old.
Primary dyschezia is a heterogenous group and is not a disease process of any particular organ but rather a symptom-based category. Primary dyschezia is not caused by dyspepsia, gastritis, reflux oesophagitis, IBS. As such, patient education regarding the causes of dyschezia is helpful, particularly given the limited options, often ineffective, for treatment.
The present investigation was designed to define the efficacy of local LLLT for the management of dyssynergic defecation (DD) and constipation. We provide support that using local LLLT has the potential to be managed as a form of complementary therapy (rather than alternative therapy). However, due to the non-significant results of this study, the lack of consistency of these results in other studies, and the necessity of large studies for further definitive conclusions, the evidence presented does not justify the use of local LLLT for the treatment of DD.